| Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials |
31 |
| Deep learning in pharmacogenomics: from gene regulation to patient stratification |
16 |
| Genotype-guided warfarin therapy: current status |
12 |
| Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward |
11 |
| Patient perspectives following pharmacogenomics results disclosure in an integrated health system |
10 |
| Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing |
10 |
| Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions |
8 |
| Pharmacogenomics education in medical and pharmacy schools: conclusions of a global survey |
8 |
| Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis |
7 |
| Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients |
7 |
| Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients |
7 |
| Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective |
7 |
| Nanopore sequencing of the pharmacogene CYP2D6 allows simultaneous haplotyping and detection of duplications |
7 |
| Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy |
6 |
| Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis |
6 |
| Pharmacogenetic testing in primary care practice: opinions of physicians, pharmacists and patients |
6 |
| Pharmacogenetics of warfarin dosing in patients of African and European ancestry |
6 |
| Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability |
6 |
| Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants |
6 |
| Pharmacogenomics courses in pharmacy school curricula |
5 |
| Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach |
5 |
| Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life |
5 |
| RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms |
5 |
| GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients |
5 |
| A systematic review of genome-wide association studies of antipsychotic response |
5 |
| Transient receptor potential polymorphism and haplotype associate with crisis pain in sickle cell disease |
5 |
| Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis |
5 |
| Genetic variations in genes of the stress response pathway are associated with prolonged abstinence from heroin |
4 |
| Role of miRNAs in treatment response and toxicity of childhood acute lymphoblastic leukemia |
4 |
| From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation |
4 |
| Systems pharmacogenomics - gene, disease, drug and placebo interactions: a case study in COMT |
4 |
| The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer |
4 |
| Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients |
4 |
| Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies |
4 |
| Pharmacogenetic landscape of DPYD variants in south Asian populations by integration of genome-scale data |
4 |
| Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study |
4 |
| Using genomics to guide treatment for glioblastoma |
4 |
| Association between genetic polymorphisms and angiotensin-converting enzyme inhibitor-induced cough: a systematic review and meta-analysis |
4 |
| Pharmacogenetic of voriconazole antifungal agent in pediatric patients |
4 |
| RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer |
4 |
| EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance |
4 |
| A stepwise approach to implementing pharmacogenetic testing in the primary care setting |
4 |
| CYP2D6 genotype analysis of a Thai population: platform comparison |
3 |
| Polymorphisms in IGF2/H19 gene locus are associated with platinum-based chemotherapeutic response in Chinese patients with epithelial ovarian cancer |
3 |
| Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes |
3 |
| NR3C1 gene polymorphisms are associated with steroid resistance in patients with primary nephrotic syndrome |
3 |
| Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients |
3 |
| The impact of OPRM1's genetic polymorphisms on methadone maintenance treatment in opioid addicts: a systematic review |
3 |
| A gene variant near ATM affects the response to metformin and metformin plasma levels: a post hoc analysis of an RCT |
3 |
| Implementation of wide-scale pharmacogenetic testing in primary care |
3 |
